ERBB2 and breast carcinoma: This study used longitudinal live cell imaging to quantify the effect of immune cell presence on trastuzumab-treated HER2 + breast cancer through in vitro co-culturing of CD4 + T-cells and HER2 + cancer cell lines (as seen in Fig. 4).